Tuberculosis (TB) is a major global health problem with about 9 million new cases and 1.7 million deaths annually [1]. The world-wide problem of TB is expected to worsen in the future due to many reasons, including the spread of drug-resistant strains of Mycobacterium tuberculosis, and TB-HIV co-infection [1]. In addition to new drugs at affordable prices, the global control of TB requires cost-effective reagents for specific diagnosis and protective vaccines [2]. At present, among the commonly used strategies to control TB in the world are the diagnoses of TB using the purified protein derivative (PPD) of M. tuberculosis in delayed-type hypersensitivity (DTH) skin responses, and immunization with Mycobacterium bovis BCG as a vaccine. However, the current data demonstrates that both of these modalities have failed to control the world-wide problem of TB [1].The major limitation of PPD is its inability to differentiate between individuals vaccinated with BCG, infected with M. tuberculosis and exposed to environmental non-tuberculous mycobacteria [3]. This is because PPD is a crude mixture of hundreds of proteins present in the culture supernatant of in vitro grown M. tuberculosis and contains both species-specific as well as crossreactive antigens [3]. On the other hand, BCG vaccination imparts inconsistent protection against TB in different parts of the world, in people of various age groups and against different clinical manifestations of the disease, which suggest that BCG may be lacking in some important antigens of M. tuberculosis required for optimal induction of protective immunity [3]. Therefore, for diagnostic as well as vaccine applications, the identification of M. tuberculosis-specific antigenic proteins may be essential [4].The availability of the complete genome sequence of M. tuberculosis in 1998 opened up the door for comprehensive genomic comparisons between mycobacterial species to identify species-specific genomic regions, and lead to the identification of 11M. tuberculosis genomic regions deleted/absent in all BCG strains used for vaccination against TB in different parts of the world [5]. It was suggested that these regions could be useful for both specific diagnosis and vaccine applications [6][7][8]. The analyses of DNA sequence present in these regions of differences (RDs) for the presence of genes and encoded proteins, by using computer-based programs for prediction of open reading frames, have suggested that RD genomic regions deleted/absent in all BCG strains could encode 89 M. tuberculosis-specific proteins [9]. As given below, studies have been performed to characterize these proteins for diagnostic applications, using sera and peripheral blood mononuclear cells from TB patients and healthy subjects in antibody and cell mediated immunity assays.To obtain the RD proteins for immunological investigations, attempts were made first to obtain them as recombinant proteins [9]. These procedures have required the in vitro amplification of RD genes using polymerase chain reaction, cloning of t...